We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Nanoform Biosensor Measures Glucose Without Needle Pricks

By HospiMedica International staff writers
Posted on 20 Sep 2012
A novel biosensor located on the patient’s body could measure glucose levels continuously using tissue fluids other than blood, such as in sweat or tears. More...


Researchers at the Fraunhofer Institute for Microelectronic Circuits and Systems (IMS; Duisburg, Germany) developed the new biosensor, which involves an electrochemical reaction that is activated with the aid of an enzyme. Glucose oxidase converts glucose into hydrogen peroxide (H2O2) and other chemicals whose concentration can be measured with a potentiostat. This measurement is used for calculating the glucose level. The special feature of the biosensor is the size of the chip, which measures just 0.5 x 2.0 millimeters, which includes the entire diagnostic system.

However, the minimal size is not the only thing that provides a substantial advantage over previous biosensors of this type; it also consumes substantially less power since it is a passive system. The sensor is able to send and receive data packages, but it can also be supplied with power through radio frequency (RF), and while earlier systems required about 500 microamperes at five volts, the new system requires less than 100 microamperes, increasing durability and allowing the patient to wear the sensor for weeks, or even months.

According to the researchers at the IMS, the noninvasive measuring devices for monitoring blood glucose levels may become the basis for a particularly useful further development in the future; the biochip could control an implanted miniature insulin pump that, based on the glucose value measured, indicates the precise amount of insulin that needs to be administered. The glucose biosensor, which is still under development, was engineered by the researchers at NovioTech (Nijmegen, The Netherlands), and could be manufactured so cost-effectively that it would be best suited for mass production.

“In the past, you used to need a circuit board the size of a half-sheet of paper, and you also had to have a driver. But even these things are no longer necessary with our new sensor,” said Tom Zimmermann, business unit manager at IMS. “It even has an integrated analog digital converter that converts the electrochemical signals into digital data. The biosensor transmits the data via a wireless interface, for example to a mobile receiver. Thus, the patient can keep a steady eye on his or her glucose level. “

Related Links:

Fraunhofer Institute for Microelectronic Circuits and Systems
NovioTech



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.